#EAU20 Theme Week - Poster Session 4: Targeted treatment and personalised management of advanced bladder cancer

EAU
Europe/Madrid GMT+2

Description

Poster Session 4

Targeted treatment and personalised management of advanced bladder cancer

Poster Session 4

Thursday 23 July

17:00 - 17:45

Location: Virtual room 1

Chairs:

M. De Santis, Berlin (DE) [Accepted]

F. Liedberg, Malmö (SE) [Accepted]

T. Seisen, Paris (FR) [Accepted]

Presentations are 2 minutes in length, followed by 2 minutes for a live discussion.

17:00 - 17:04

1058 Cost-effectiveness analysis of the phase 3 IMvigor130 study evaluating atezolizumab as monotherapy or combined with platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic urothelial cancer

D.E. Magee, Toronto (CA) [Accepted]

By: Magee D.E. 1 , Cheung D.C. 1 , Hird A.E. 1 , Sridhar S.S. 2 , Fallah-Rad N. 2 , Fleshner N.E. 3 , Kulkarni G.K. 3

1University of Toronto, Dept. of Urology, Dept. of Surgery, Toronto, Canada, 2University of Toronto, Dept. of Medical Oncology, Department of Internal Medicine, University Health Network, Toronto, Canada, 3University of Toronto, Dept. of Urology, Dept. of Surgery, University Health Network, Toronto, Canada

17:04 - 17:08

1056 Interim results of PEANUT: An open-label, single-arm, phase 2 study evaluating pembrolizumab plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC)

A. Necchi, Milan (IT) [Accepted]

By: Necchi A. 1 , Raggi D. 1 , Bandini M. 2 , Farè E. 1 , Giannatempo P. 1 , Colecchia M. 1 , Pederzoli F. 2 , Gallina A. 2 , Marandino L. 1 , Calareso G. 1 , Madison R. 3 , Briganti A. 2 , Ross J. 3 , Montorsi F. 2

1Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, 3Foundation Medicine, Dept. of FMI, Cambridge, United States of America

17:08 - 17:12

768 Preliminary results of a European multicentre phase 1 study with Oncofid-P-B for the treatment of BCG unresponsive carcinoma in situ (CIS) of bladder at the end of 12 consecutive weeks intensive course and during ongoing monthly maintenance phase

R. Hurle, Bergamo (IT) [Accepted]

By: Hurle R. 1 , Guazzoni G. 2 , Colombo P. 3 , Santoro A. 4 , De Cobelli O. 5 , Di Trapani E. 5 , Nohales G. 6 , Carlos L. 7 , Duran-Merino R. 8 , Lazzeri M. 1

1IRCCS Humanitas Clinical and Research Hospital, Dept. of Urology, Rozzano, Italy, 2IRCCS Humanitas Clinical and Research Hospital - Humanitas University, Dept. of Urology, Rozzano, Italy, 3IRCCS Humanitas Clinical and Research Hospital, Dept. of Pathology, Rozzano, Italy, 4IRCCS Humanitas Clinical and Research Hospital - Humanitas University, Dept. of Oncology, Rozzano, Italy, 5IEO, Dept. of Urology, Milan, Italy, 6Hospital del Mar, Dept. of Urology, Barcelona, Spain, 7Hospital Universitario Fundacion Alcorcon, Dept. of Urology, Madrid, Spain, 8H.G.U. , Dept. of Urology, Madrid, Spain

17:12 - 17:16

66 Impact of molecular subtyping and immune infiltration on response and outcome following neoadjuvant pembrolizumab (pembro), versus neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer

A. Necchi, Milan (IT) [Accepted]

By: Necchi A. 1 , Raggi D. 1 , Briganti A. 2 , Farè E. 1 , Giannatempo P. 1 , Marandino L. 1 , Gallina A. 2 , Colecchia M. 1 , Lucianò R. 2 , Bianchi M. 2 , Colombo R. 2 , Salonia A. 2 , Gandaglia G. 2 , Fossati N. 2 , Capitanio U. 2 , Montorsi F. 2 , Boormans J. 3 , Liu Y. 4 , De Jong J. 3 , Dittamore R. 4 , Davicioni E. 4 , Black P. 5 , Gibb E. 4

1Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, 3Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands, 4Decipher Biosciences, Decipher Biosciences, Vancouver, Canada, 5University of British Columbia, Dept. of Urology, Vancouver, Canada

17:16 - 17:20

4 Randomized phase III trial of dose-dense MVAC or GC as perioperative chemotherapy for muscle-invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses

C. Pfister, Bois Guillaume (FR) [Accepted]

By: Pfister C. 1 , Gravis G. 2 , Flechon A. 3 , Soulie M. 4 , Guy L. 5 , Laguerre B. 6 , Mottet N. 7 , Joly F. 8 , Allory Y. 9 , Harter V. 10 , Culine S. 11

1Rouen University Hospital, Dept. of Urology, Rouen, France, 2Paoli-Calmette Institute, Dept. of Oncology, Marseille, France, 3Leon Berard Cancer Center, Dept. of Oncology, Lyon, France, 4Rangueil University Hospital, Dept. of Urology, Toulouse, France, 5Clermont Ferrand University Hospital, Dept. of Urology, Clermont-Ferrand, France, 6Marquis Cancer Center, Dept. of Oncology, Rennes, France, 7Saint Etienne University Hospital, Dept. of Urology, Saint Etienne, France, 8Baclesse Cancer Center, Dept. of Oncology, Caen, France, 9Curie Cancer Institute, Dept. of Pathology, Paris, France, 10Baclesse Cancer Center, NW Canceropole Data Center, Caen, France, 11Saint Louis University Hospital, Dept. of Oncology, Paris, France

Notes

Will not join live Q and A

17:20 - 17:24

2 The supplementary GM-CSF to neoadjuvant gemicitabine-cisplatin systemic chemotherapy plus PD-L1 blockade decrease local tumor recurrence of urothelial carcinoma after surgery via suppression of MDSCs in blood and tumor microevironment

M. Miyake, Nara (JP) [Invited]

By: Miyake M. 1 , Hori S. 1 , Nishimura N. 1 , Owari T. 1 , Itami Y. 1 , Nakai Y. 1 , Tanaka N. 1 , Fujimoto K. 1

1Nara Medical University, Dept. of Urology, Nara, Japan

Notes

18/7: Not accepted, no upload

17:24 - 17:28

908 The diagnostic accuracy of Bladder EpiCheck in high-risk population

M. Racioppi, Rome (IT) [Invited]

By: Racioppi M. 1 , Di Gianfrancesco L. 2 , Ragonese M. 2 , Palermo G. 2 , Sacco E. 2 , Bassi P.F. 2

1Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Dept. of Urology, Rome, Italy, 2Fondazione Policlinico Universitario, Dept. of Urology, Rome, Italy

Notes

18/7: Not accepted, no upload

17:28 - 17:32

902 Xpert®️ bladder cancer monitor in the follow up of patients affected by non muscle invasive bladder cancer (NMIBC): An update

C. D'Elia, Bolzano (IT) [Accepted]

By: D'Elia C. 1 , Trenti E. 1 , Folchini D.M.F. 1 , Pycha S. 2 , Mian C. 3 , Schwienbacher C. 3 , Hanspeter E. 3 , Pycha A. 1

1Bolzano General Hospital, Dept. of Urology, Bolzano, Italy, 2Riga Stradins University, Dept. of Medicine, Riga, Latvia, 3Bolzano General Hospital, Dept. of Pathology, Bolzano, Italy

17:32 - 17:36

901 Evaluation of ADXBLADDER and cytology performance in the follow up of NMIBC: A blinded prospective multicentric study

P. Gontero, Turin (IT) [Accepted]

By: Gontero P. 1 , Montanari E. 2 , Roupret M. 3 , Longo F. 2 , Stockley J. 4 , Kennedy A. 4 , Rodríguez Ó. 5 , Sieverink C. 6 , Vanié F. 7 , Allasia M. 1 , Witjes J.A. 6 , Colombel M. 8 , Sylvester R. 9 , McCracken S. 10 , Dudderidge T. 11 , Palou J. 5

1Ospedale Molinette, Dept. of Urology, Turin, Italy, 2Universita’ Policlinico Milano, Dept. of Urology, Milan, Italy, 3Hôpital Pitié-Salpétrière, Sorbonne University, Dept. of Urology, Paris, France, 4Arquer Diagnostics, Dept. of R&D, Sunderland, United Kingdom, 5Fundacio Puigvert, Dept. of Urology, Barcelona, Spain, 6Radboud University Medical Centre, Dept. of Urology, Nijmegen, The Netherlands, 7Hôpital Pitié-Salpétrière, Dept. of Urology, Paris, France, 8Hôpital Edouard Herriot, Dept. of Urology, Lyon, France, 9EAU Non-muscle Invasive Guidelines Panel, EAU Guidelines Office, Brussels, Belgium, 10Sunderland Royal Hospital, Dept. of Urology, Sunderland, United Kingdom, 11University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom

17:36 - 17:40

531 Prospective validation of vesical imaging-reporting and data system (VI-RADS) for non-muscle invasive (NMI) vs. muscle invasive bladder cancer (MIBC) discrimination in patients candidate for primary transurethral resection of bladder tumors (TURBT)κκκ

M. Pecoraro, san cipriano picentino (IT) [Accepted]

By: Pecoraro M. 1 , Del Giudice F. 2 , Campa R. 1 , Cipollari S. 1 , Salvo V. 1 , Bicchetti M. 1 , Sciarra A. 2 , Simone G. 3 , Gallucci M. 2 , Leonardo C. 2 , De Berardinis E. 2 , Catalano C. 1 , Panebianco V. 1

1Sapienza Rome University, Dept. of Radiology, Rome, Italy, 2Sapienza Rome University, Dept. of Urology, Rome, Italy, 3Regina Elena Cancer Institute, Dept. of Urology, Rome, Italy

Maria De Santis, Fredrik Liedberg, Thomas Seisen

Cost-effectiveness analysis of the phase 3 IMvigor130 study evaluating atezolizumab as monotherapy or combined with platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic urothelial cancer

Inglês

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES
 

Speakers

D.E. Magee, A. Necchi, R. Hurle, C. Pfister, M. Miyake, M. Racioppi, C. D'Elia, P. Gontero, M. Pecoraro

 

Link to the Event

Banner to the Event

#EAU20 Theme Week - Poster Session 4: Targeted treatment and personalised management of advanced bladder cancer
 
 
 

Download the Agenda

Search for our next event. See you soon!

Subscribe to get news on all upcoming events

who%20goals_edited.png

DocMeeetings

Social Media

  • Twitter DocMeetings
  • Instagram DocMeetings
  • Facebook ícone social
  • LinkedIn ícone social

contact us

Adress

Sao Paulo, SP - Brazil

© 2020 by Docmeetings - A DocMeetings.com Company
Site Managed by:
QUALITY Soluções Web
1996-2020 "24 years inspiring technology"